marketcaparena
Search

    OGN

    Organon & Co.

    Company overview

    Market capitalization
    $3.61B
    Employees
    10,000
    Latest publication
    2026-09-29
    About Organon & Co.

    Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue1,558,000,000USD1,460,000,000USD1,507,000,000USD1,602,000,000USD1,594,000,000USD1,513,000,000USD1,592,000,000USD1,582,000,000USD
    Cost Of Revenue711,000,000USD677,000,000USD748,000,000USD745,000,000USD720,000,000USD672,000,000USD696,000,000USD659,000,000USD
    Gross Profit847,000,000USD783,000,000USD759,000,000USD857,000,000USD874,000,000USD841,000,000USD896,000,000USD923,000,000USD
    Selling General Administrative434,000,000USD424,000,000USD433,000,000USD415,000,000USD453,000,000USD420,000,000USD262,000,000USD422,000,000USD
    Total Operating Expenses434,000,000USD517,000,000USD524,000,000USD499,000,000USD548,000,000USD516,000,000USD600,000,000USD533,000,000USD
    Operating Income413,000,000USD266,000,000USD235,000,000USD358,000,000USD326,000,000USD325,000,000USD296,000,000USD390,000,000USD
    Total Other Income Expense Net-230,000,000USD-53,000,000USD-383,000,000USD-115,000,000USD-97,000,000USD-224,000,000USD-167,000,000USD-183,000,000USD
    Interest Expense108,000,000USD111,000,000USD121,000,000USD128,000,000USD132,000,000USD124,000,000USD132,000,000USD126,000,000USD
    Income Before Tax183,000,000USD213,000,000USD-148,000,000USD243,000,000USD229,000,000USD101,000,000USD129,000,000USD207,000,000USD
    Income Tax Expense75,000,000USD67,000,000USD57,000,000USD83,000,000USD84,000,000USD14,000,000USD20,000,000USD-152,000,000USD
    Net Income108,000,000USD146,000,000USD-205,000,000USD160,000,000USD145,000,000USD87,000,000USD109,000,000USD359,000,000USD
    Research Development—93,000,000USD91,000,000USD84,000,000USD95,000,000USD96,000,000USD130,000,000USD111,000,000USD
    Net Interest Income—-111,000,000USD-121,000,000USD-128,000,000USD-131,000,000USD-124,000,000USD-132,000,000USD-126,000,000USD
    Tax Provision—67,000,000USD57,000,000USD83,000,000USD84,000,000USD14,000,000USD20,000,000USD-152,000,000USD
    Net Income From Continuing Ops—146,000,000USD-205,000,000USD160,000,000USD145,000,000USD87,000,000USD109,000,000USD359,000,000USD
    Ebit—324,000,000USD-27,000,000USD371,000,000USD360,000,000USD225,000,000USD265,000,000USD333,000,000USD
    Ebitda—409,000,000USD65,000,000USD460,000,000USD449,000,000USD325,000,000USD341,000,000USD402,000,000USD
    Depreciation And Amortization—85,000,000USD92,000,000USD89,000,000USD89,000,000USD100,000,000USD76,000,000USD69,000,000USD
    Reconciled Depreciation—86,000,000USD96,000,000USD92,000,000USD89,000,000USD84,000,000USD77,000,000USD69,000,000USD
    Net Income Applicable To Common Shares——-205,000,000USD160,000,000USD145,000,000USD87,000,000USD109,000,000USD359,000,000USD
    Selling And Marketing Expenses——————206,000,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20172017-12-31 · USD
    Total Revenue6,216,000,000USD6,403,000,000USD6,263,000,000USD6,174,000,000USD6,304,000,000USD6,532,000,000USD7,777,000,000USD10,500,000,000USD
    Cost Of Revenue2,854,000,000USD2,688,000,000USD2,515,000,000USD2,294,000,000USD2,382,000,000USD2,119,000,000USD2,274,000,000USD4,588,000,000USD
    Gross Profit3,362,000,000USD3,715,000,000USD3,748,000,000USD3,880,000,000USD3,922,000,000USD4,413,000,000USD5,503,000,000USD5,912,000,000USD
    Research Development366,000,000USD469,000,000USD528,000,000USD471,000,000USD443,000,000USD210,000,000USD220,000,000USD355,000,000USD
    Selling General Administrative1,721,000,000USD1,552,000,000USD1,682,000,000USD1,449,000,000USD1,432,000,000USD1,158,000,000USD1,181,000,000USD1,929,000,000USD
    Total Operating Expenses2,087,000,000USD2,229,000,000USD2,421,000,000USD2,175,000,000USD2,007,000,000USD1,566,000,000USD1,663,000,000USD2,640,000,000USD
    Operating Income1,285,000,000USD1,486,000,000USD1,327,000,000USD1,705,000,000USD1,915,000,000USD2,847,000,000USD3,847,000,000USD3,272,000,000USD
    Interest Expense504,000,000USD520,000,000USD527,000,000USD422,000,000USD258,000,000USD6,000,000USD6,000,000USD21,000,000USD
    Net Interest Income-504,000,000USD-520,000,000USD-517,000,000USD-422,000,000USD-258,000,000USD0USD0USD—
    Income Before Tax425,000,000USD807,000,000USD673,000,000USD1,122,000,000USD1,529,000,000USD2,752,000,000USD3,696,000,000USD3,099,000,000USD
    Income Tax Expense238,000,000USD-57,000,000USD-350,000,000USD205,000,000USD178,000,000USD496,000,000USD390,000,000USD1,298,000,000USD
    Tax Provision238,000,000USD-57,000,000USD95,000,000USD205,000,000USD178,000,000USD520,000,000USD337,000,000USD1,298,000,000USD
    Net Income187,000,000USD864,000,000USD1,023,000,000USD917,000,000USD1,351,000,000USD2,160,000,000USD3,218,000,000USD1,801,000,000USD
    Net Income From Continuing Ops187,000,000USD864,000,000USD585,000,000USD917,000,000USD1,351,000,000USD2,160,000,000USD3,218,000,000USD—
    Ebit929,000,000USD1,327,000,000USD1,200,000,000USD1,544,000,000USD1,787,000,000USD2,847,000,000USD3,561,000,000USD3,106,000,000USD
    Ebitda1,282,333,245USD1,604,000,000USD1,436,000,000USD1,756,000,000USD1,982,000,000USD2,989,000,000USD3,915,000,000USD5,079,000,000USD
    Depreciation And Amortization353,333,245USD277,000,000USD236,000,000USD212,000,000USD195,000,000USD142,000,000USD354,000,000USD1,973,000,000USD
    Reconciled Depreciation361,000,000USD277,000,000USD228,000,000USD212,000,000USD195,000,000USD157,000,000USD354,000,000USD—
    Total Other Income Expense Net-860,000,000USD-679,000,000USD-654,000,000USD-583,000,000USD-386,000,000USD-95,000,000USD-144,000,000USD-173,000,000USD
    Net Income Applicable To Common Shares187,000,000USD864,000,000USD1,023,000,000USD917,000,000USD1,351,000,000USD2,160,000,000USD3,218,000,000USD1,801,000,000USD
    Selling And Marketing Expenses—206,000,000USD209,000,000USD255,000,000USD—198,000,000USD262,000,000USD356,000,000USD
    Unclassified Operating Expenses————132,000,000USD———
    Discontinued Operations—————-96,000,000USD-88,000,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets13,178,000,000USD12,996,000,000USD12,867,000,000USD13,552,000,000USD13,500,000,000USD13,156,000,000USD13,101,000,000USD12,752,000,000USD
    Cash And Equivalents1,132,000,000USD—574,000,000USD672,000,000USD599,000,000USD547,000,000USD675,000,000USD763,000,000USD
    Total Current Assets5,111,000,000USD4,932,000,000USD4,352,000,000USD4,700,000,000USD4,618,000,000USD4,371,000,000USD4,348,000,000USD4,756,000,000USD
    Other Current Assets1,136,000,000USD1,058,000,000USD939,000,000USD1,019,000,000USD1,054,000,000USD995,000,000USD861,000,000USD881,000,000USD
    Total Liabilities12,172,000,000USD———————
    Total Current Liabilities2,616,000,000USD2,500,000,000USD2,390,000,000USD2,679,000,000USD2,796,000,000USD2,615,000,000USD2,718,000,000USD2,790,000,000USD
    Other Non Current Liabilities1,026,000,000USD———————
    Total Stockholder Equity1,006,000,000USD903,000,000USD752,000,000USD906,000,000USD733,000,000USD542,000,000USD472,000,000USD493,000,000USD
    Total Equity Including Noncontrolling Interest1,006,000,000USD———————
    Long Term Debt8,479,000,000USD8,553,000,000USD8,628,000,000USD8,783,000,000USD8,781,000,000USD8,936,000,000USD8,860,000,000USD8,739,000,000USD
    Net Receivables1,492,000,000USD1,385,000,000USD1,433,000,000USD1,521,000,000USD1,511,000,000USD1,467,000,000USD1,491,000,000USD1,729,000,000USD
    Inventory1,351,000,000USD1,373,000,000USD1,406,000,000USD1,488,000,000USD1,454,000,000USD1,362,000,000USD1,321,000,000USD1,383,000,000USD
    Property Plant Equipment Net1,281,000,000USD1,279,000,000USD1,303,000,000USD1,290,000,000USD1,266,000,000USD1,197,000,000USD1,325,000,000USD1,204,000,000USD
    Goodwill4,153,000,000USD———————
    Accounts Payable1,051,000,000USD983,000,000USD952,000,000USD1,074,000,000USD1,067,000,000USD1,006,000,000USD1,153,000,000USD1,092,000,000USD
    Short Term Debt74,000,000USD16,000,000USD56,000,000USD45,000,000USD115,000,000USD20,000,000USD64,000,000USD10,000,000USD
    Common Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Retained Earnings1,352,000,000USD1,253,000,000USD1,109,000,000USD1,318,000,000USD1,163,000,000USD1,026,000,000USD1,010,000,000USD975,000,000USD
    Accumulated Other Comprehensive Income-548,000,000USD-539,000,000USD-527,000,000USD-574,000,000USD-572,000,000USD-617,000,000USD-649,000,000USD-571,000,000USD
    Intangible Assets—1,099,000,000USD1,130,000,000USD1,340,000,000USD1,362,000,000USD1,417,000,000USD1,414,000,000USD763,000,000USD
    Total Liab—12,093,000,000USD12,115,000,000USD12,646,000,000USD12,767,000,000USD12,614,000,000USD12,629,000,000USD12,259,000,000USD
    Other Current Liab—1,424,000,000USD1,382,000,000USD1,444,000,000USD1,420,000,000USD1,413,000,000USD1,367,000,000USD1,458,000,000USD
    Capital Stock—3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Good Will—4,153,000,000USD4,153,000,000USD4,680,000,000USD4,680,000,000USD4,680,000,000USD4,680,000,000USD4,603,000,000USD
    Cash—1,116,000,000USD574,000,000USD672,000,000USD599,000,000USD547,000,000USD675,000,000USD763,000,000USD
    Cash And Short Term Investments—1,116,000,000USD574,000,000USD672,000,000USD599,000,000USD547,000,000USD675,000,000USD763,000,000USD
    Net Debt—7,453,000,000USD8,226,000,000USD8,156,000,000USD8,297,000,000USD8,409,000,000USD8,361,000,000USD7,986,000,000USD
    Short Long Term Debt—16,000,000USD16,000,000USD45,000,000USD115,000,000USD20,000,000USD20,000,000USD10,000,000USD
    Short Long Term Debt Total—8,569,000,000USD8,800,000,000USD8,828,000,000USD8,896,000,000USD8,956,000,000USD9,036,000,000USD8,749,000,000USD
    Common Stock Shares Outstanding—262,896,000shares260,172,000shares260,653,000shares260,156,000shares261,001,000shares259,878,000shares259,757,000shares
    Non Current Assets Total—8,064,000,000USD8,515,000,000USD8,852,000,000USD8,882,000,000USD8,785,000,000USD8,753,000,000USD7,996,000,000USD
    Non Current Liabilities Total—9,593,000,000USD9,725,000,000USD9,967,000,000USD9,971,000,000USD9,999,000,000USD9,911,000,000USD9,469,000,000USD
    Non Current Liabilities Other—984,000,000USD1,008,000,000USD1,122,000,000USD1,121,000,000USD994,000,000USD977,000,000USD674,000,000USD
    Non Currrent Assets Other—1,533,000,000USD1,929,000,000USD1,542,000,000USD1,574,000,000USD1,489,000,000USD361,000,000USD1,425,944,000USD
    Net Working Capital—2,432,000,000USD1,962,000,000USD2,021,000,000USD1,822,000,000USD1,756,000,000USD1,630,000,000USD1,966,000,000USD
    Unclassified Current Liabilities—61,000,000USD—71,000,000USD79,000,000USD156,000,000USD114,000,000USD220,000,000USD
    Unclassified Equity—183,000,000USD164,000,000USD156,000,000USD136,000,000USD127,000,000USD105,000,000USD83,000,000USD
    Other Assets——1,774,000,000USD1,542,000,000USD1,574,000,000USD1,491,000,000USD1,334,000,000USD1,426,000,000USD
    Property Plant Equipment Gross——2,542,000,000USD———2,228,000,000USD—
    Unclassified Non Current Assets——-1,774,000,000USD-1,542,000,000USD-1,574,000,000USD-1,489,000,000USD-361,000,000USD-1,425,944,000USD
    Short Term Investments———————-762,237,000USD
    Unclassified Current Assets———————762,237,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets12,867,000,000USD13,101,000,000USD12,058,000,000USD10,955,000,000USD10,681,000,000USD10,109,000,000USD10,548,000,000USD10,494,000,000USD
    Intangible Assets1,130,000,000USD1,414,000,000USD533,000,000USD649,000,000USD651,000,000USD503,000,000USD569,000,000USD812,000,000USD
    Other Current Assets939,000,000USD861,000,000USD643,000,000USD616,000,000USD596,000,000USD1,237,000,000USD992,000,000USD883,000,000USD
    Total Liab12,115,000,000USD12,629,000,000USD12,128,000,000USD11,847,000,000USD12,189,000,000USD4,623,000,000USD3,513,000,000USD4,146,000,000USD
    Total Stockholder Equity752,000,000USD472,000,000USD-70,000,000USD-892,000,000USD-1,508,000,000USD5,486,000,000USD7,035,000,000USD6,348,000,000USD
    Other Current Liab1,382,000,000USD1,367,000,000USD1,343,000,000USD1,139,000,000USD975,000,000USD2,118,000,000USD793,000,000USD497,000,000USD
    Common Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD6,108,000,000USD7,949,000,000USD7,256,000,000USD
    Capital Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD0USD—
    Retained Earnings1,109,000,000USD1,010,000,000USD443,000,000USD-331,000,000USD-998,000,000USD-219,000,000USD0USD—
    Good Will4,153,000,000USD4,680,000,000USD4,603,000,000USD4,603,000,000USD4,603,000,000USD4,603,000,000USD4,603,000,000USD4,603,000,000USD
    Other Assets1,774,000,000USD1,334,000,000USD1,058,000,000USD539,000,000USD464,000,000USD347,000,000USD659,000,000USD714,000,000USD
    Cash574,000,000USD675,000,000USD693,000,000USD706,000,000USD737,000,000USD12,000,000USD319,000,000USD244,000,000USD
    Cash And Equivalents574,000,000USD675,000,000USD693,000,000USD706,000,000USD737,000,000USD12,000,000USD319,000,000USD244,000,000USD
    Cash And Short Term Investments574,000,000USD675,000,000USD693,000,000USD706,000,000USD737,000,000USD12,000,000USD319,000,000USD244,000,000USD
    Total Current Assets4,352,000,000USD4,348,000,000USD4,508,000,000USD3,931,000,000USD3,760,000,000USD3,567,000,000USD3,955,000,000USD3,714,000,000USD
    Total Current Liabilities2,390,000,000USD2,718,000,000USD2,918,000,000USD2,512,000,000USD2,597,000,000USD2,673,000,000USD1,341,000,000USD1,545,000,000USD
    Net Debt8,226,000,000USD8,361,000,000USD8,238,000,000USD8,406,000,000USD8,627,000,000USD19,000,000USD-133,000,000USD-95,000,000USD
    Short Term Debt56,000,000USD64,000,000USD55,000,000USD57,000,000USD55,000,000USD8,000,000USD48,000,000USD-207,000,000USD
    Short Long Term Debt16,000,000USD20,000,000USD9,000,000USD8,000,000USD9,000,000USD1,339,000,000USD34,000,000USD—
    Short Long Term Debt Total8,800,000,000USD9,036,000,000USD8,931,000,000USD9,112,000,000USD9,364,000,000USD31,000,000USD186,000,000USD149,000,000USD
    Long Term Debt8,628,000,000USD8,860,000,000USD8,751,000,000USD8,905,000,000USD9,125,000,000USD0USD70,000,000USD34,000,000USD
    Net Receivables1,433,000,000USD1,491,000,000USD1,857,000,000USD1,606,000,000USD1,512,000,000USD1,405,000,000USD1,573,000,000USD1,593,000,000USD
    Inventory1,406,000,000USD1,321,000,000USD1,315,000,000USD1,003,000,000USD915,000,000USD913,000,000USD1,071,000,000USD994,000,000USD
    Accounts Payable952,000,000USD1,153,000,000USD1,314,000,000USD1,132,000,000USD1,382,000,000USD259,000,000USD258,000,000USD289,000,000USD
    Property Plant Equipment Net1,303,000,000USD1,325,000,000USD1,356,000,000USD1,233,000,000USD1,203,000,000USD1,015,000,000USD762,000,000USD651,000,000USD
    Property Plant Equipment Gross2,542,000,000USD2,228,000,000USD2,200,000,000USD1,920,000,000USD1,855,000,000USD984,000,000USD680,000,000USD—
    Accumulated Other Comprehensive Income-527,000,000USD-649,000,000USD-541,000,000USD-564,000,000USD-513,000,000USD-622,000,000USD-914,000,000USD-908,000,000USD
    Common Stock Shares Outstanding260,764,000shares259,152,000shares256,269,999shares255,169,000shares253,550,029shares253,516,000shares253,130,375shares253,130,375shares
    Non Current Assets Total8,515,000,000USD8,753,000,000USD7,550,000,000USD7,024,000,000USD6,921,000,000USD6,542,000,000USD6,593,000,000USD6,780,000,000USD
    Non Current Liabilities Total9,725,000,000USD9,911,000,000USD9,210,000,000USD9,335,000,000USD9,592,000,000USD1,950,000,000USD2,172,000,000USD2,601,000,000USD
    Non Current Liabilities Other1,008,000,000USD977,000,000USD412,000,000USD411,000,000USD463,000,000USD9,932,000,000USD1,963,000,000USD—
    Non Currrent Assets Other1,929,000,000USD361,000,000USD250,000,000USD272,000,000USD464,000,000USD421,000,000USD659,000,000USD714,000,000USD
    Net Working Capital1,962,000,000USD1,630,000,000USD1,590,000,000USD1,419,000,000USD1,163,000,000USD2,233,000,000USD2,614,000,000USD—
    Unclassified Non Current Assets-1,774,000,000USD-361,000,000USD-250,000,000USD-272,000,000USD-464,000,000USD-347,000,000USD-659,000,000USD-714,000,000USD
    Unclassified Equity164,000,000USD105,000,000USD22,000,000USD——216,000,000USD——
    Unclassified Current Liabilities—114,000,000USD—157,000,000USD176,000,000USD-1,051,000,000USD208,000,000USD437,000,000USD
    Current Deferred Revenue——206,000,000USD19,000,000USD—-8,000,000USD—322,000,000USD
    Other Liab———280,000,000USD283,000,000USD1,879,000,000USD2,034,000,000USD2,567,000,000USD
    Net Tangible Assets———-6,144,000,000USD-6,904,000,000USD380,000,000USD1,863,000,000USD933,000,000USD
    Unclassified Non Current Liabilities———-261,000,000USD-283,000,000USD-9,861,000,000USD-1,895,000,000USD—
    Deferred Long Term Liab————4,000,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income146,000,000USD-205,000,000USD160,000,000USD145,000,000USD87,000,000USD109,000,000USD359,000,000USD195,000,000USD
    Depreciation86,000,000USD239,856,000USD92,000,000USD89,000,000USD84,000,000USD77,000,000USD69,000,000USD66,000,000USD
    Stock Based Compensation19,000,000USD7,000,000USD24,000,000USD22,000,000USD24,000,000USD26,000,000USD25,000,000USD28,000,000USD
    Other Non Cash Items-71,000,000USD103,144,000USD-25,000,000USD15,000,000USD22,000,000USD56,000,000USD51,000,000USD22,000,000USD
    Change To Account Receivables-65,000,000USD160,000,000USD-5,000,000USD9,000,000USD-85,000,000USD341,000,000USD-46,000,000USD-75,000,000USD
    Change To Inventory-9,000,000USD81,000,000USD-63,000,000USD-34,000,000USD3,000,000USD-31,000,000USD-61,000,000USD-58,000,000USD
    Change In Working Capital42,000,000USD-34,000,000USD-27,000,000USD-61,000,000USD-125,000,000USD112,000,000USD-167,000,000USD-301,000,000USD
    Total Cash From Operating Activities225,000,000USD141,000,000USD264,000,000USD220,000,000USD75,000,000USD390,000,000USD141,000,000USD332,000,000USD
    Capital Expenditures-37,000,000USD-45,000,000USD-115,000,000USD-39,000,000USD-97,000,000USD-132,000,000USD-76,000,000USD-32,000,000USD
    Free Cash Flow188,000,000USD96,000,000USD149,000,000USD181,000,000USD-22,000,000USD258,000,000USD65,000,000USD300,000,000USD
    Total Cashflows From Investing Activities386,000,000USD-65,000,000USD-115,000,000USD-38,000,000USD-172,000,000USD-296,000,000USD-75,000,000USD-46,000,000USD
    Net Borrowings-32,000,000USD-182,000,000USD-72,000,000USD-201,000,000USD-3,000,000USD-2,000,000USD-2,000,000USD—
    Total Cash From Financing Activities-38,000,000USD-187,000,000USD-76,000,000USD-223,000,000USD-75,000,000USD-82,000,000USD-78,000,000USD-134,000,000USD
    Dividends Paid-5,000,000USD-4,000,000USD-3,000,000USD-10,000,000USD-71,000,000USD-74,000,000USD-74,000,000USD-79,000,000USD
    Change In Cash542,000,000USD-98,000,000USD73,000,000USD52,000,000USD-128,000,000USD-88,000,000USD59,000,000USD129,000,000USD
    Begin Period Cash Flow574,000,000USD672,000,000USD599,000,000USD547,000,000USD675,000,000USD763,000,000USD704,000,000USD575,000,000USD
    End Period Cash Flow1,116,000,000USD574,000,000USD672,000,000USD599,000,000USD547,000,000USD675,000,000USD763,000,000USD704,000,000USD
    Other Cashflows From Financing Activities-1,000,000USD-1,000,000USD-1,000,000USD60,919,000USD-1,000,000USD-4,000,000USD-2,000,000USD1,000,000,000USD
    Unclassified Operating Cash Flow3,000,000USD30,000,000USD40,000,000USD10,000,000USD-17,000,000USD10,000,000USD-196,000,000USD322,000,000USD
    Unclassified Investing Cash Flow423,000,000USD-363,701,000USD115,069,000USD38,000,000USD162,000,000USD130,073,000USD75,000,000USD46,000,000USD
    Other Cashflows From Investing Activities—343,701,000USD-69,000USD1,000,000USD-65,000,000USD1,927,000USD1,000,000USD-14,000,000USD
    Investments——-115,000,000USD-38,000,000USD-172,000,000USD-296,000,000USD-75,000,000USD-46,000,000USD
    Sale Purchase Of Stock——-1,000,000USD-12,000,000USD-1,000,000USD-4,000,000USD-2,000,000USD-14,000,000USD
    Unclassified Financing Cash Flow———-60,919,000USD—2,000,000USD2,000,000USD-1,041,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Net Income187,000,000USD864,000,000USD1,023,000,000USD917,000,000USD1,351,000,000USD2,153,000,000USD1,801,000,000USD
    Depreciation361,000,000USD277,000,000USD236,000,000USD212,000,000USD195,000,000USD1,673,000,000USD1,973,000,000USD
    Stock Based Compensation77,000,000USD105,000,000USD101,000,000USD75,000,000USD59,000,000USD56,000,000USD56,000,000USD
    Other Non Cash Items259,000,000USD131,000,000USD79,000,000USD124,000,000USD439,000,000USD-58,000,000USD5,480,000,000USD
    Change To Account Receivables79,000,000USD383,000,000USD-212,000,000USD-123,000,000USD-277,000,000USD250,000,000USD533,000,000USD
    Change To Inventory-13,000,000USD-131,000,000USD-230,000,000USD-220,000,000USD-138,000,000USD44,000,000USD72,000,000USD
    Change In Working Capital-247,000,000USD-278,000,000USD-155,000,000USD-452,000,000USD702,000,000USD-174,000,000USD-1,435,000,000USD
    Total Cash From Operating Activities700,000,000USD939,000,000USD799,000,000USD858,000,000USD2,458,000,000USD3,687,000,000USD3,419,000,000USD
    Capital Expenditures-162,000,000USD-351,000,000USD-261,000,000USD-427,000,000USD-488,000,000USD-101,000,000USD-86,000,000USD
    Free Cash Flow538,000,000USD588,000,000USD538,000,000USD431,000,000USD1,970,000,000USD3,586,000,000USD3,333,000,000USD
    Total Cashflows From Investing Activities-390,000,000USD-513,000,000USD-260,000,000USD-420,000,000USD-481,000,000USD-69,000,000USD-56,000,000USD
    Net Borrowings-458,000,000USD-11,000,000USD-258,000,000USD-108,000,000USD7,728,000,000USD59,000,000USD-4,000,000USD
    Total Cash From Financing Activities-561,000,000USD-368,000,000USD-569,000,000USD-433,000,000USD-1,333,000,000USD-4,164,000,000USD-3,372,000,000USD
    Dividends Paid-88,000,000USD-297,000,000USD-294,000,000USD-290,000,000USD-145,000,000USD-145,000,000USD—
    Change In Cash-101,000,000USD-18,000,000USD-13,000,000USD-31,000,000USD667,000,000USD-527,000,000USD-45,000,000USD
    Begin Period Cash Flow675,000,000USD693,000,000USD706,000,000USD737,000,000USD70,000,000USD771,000,000USD816,000,000USD
    End Period Cash Flow574,000,000USD675,000,000USD693,000,000USD706,000,000USD737,000,000USD244,000,000USD771,000,000USD
    Other Cashflows From Investing Activities-390,000,000USD4,000,000USD1,000,000USD-117,000,000USD-289,000,000USD32,000,000USD30,000,000USD
    Other Cashflows From Financing Activities-15,000,000USD-38,000,000USD-17,000,000USD-35,000,000USD436,000,000USD-4,223,000,000USD-3,368,000,000USD
    Unclassified Operating Cash Flow63,000,000USD-160,000,000USD-485,000,000USD-18,000,000USD-288,000,000USD37,000,000USD-4,456,000,000USD
    Unclassified Investing Cash Flow162,000,000USD347,000,000USD240,000,000USD544,000,000USD777,000,000USD69,000,000USD—
    Investments—-513,000,000USD-240,000,000USD-420,000,000USD-481,000,000USD-69,000,000USD—
    Sale Purchase Of Stock—-22,000,000USD-17,000,000USD-11,000,000USD———
    Unclassified Financing Cash Flow——17,000,000USD11,000,000USD-9,352,000,000USD145,000,000USD—
    Change To Liabilities———-237,000,000USD709,000,000USD20,000,000USD-14,000,000USD
    Cash And Cash Equivalents Changes————702,000,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductArcoxia69,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductAtozet80,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBildvos Bilprevda19,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBrenzys14,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductClarinex30,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCozaar Hyzaar50,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductDiprospan44,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductDulera41,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductEmgality Ravvow54,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductFollistim AQ59,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductFosamax25,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductGanirelix Acetate Injection26,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductHadlima79,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductJada0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductMarvelon Mercilon32,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNasonex58,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNexplanon Implanon NXT230,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNuva Ring27,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOntruzant6,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Biosimilars12,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Cardiovascular25,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Non Opiod Pain Bone And Dermatology79,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Respiratory18,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Sundry Established Brands96,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Sundry Products14,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Womens Health45,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductPropecia36,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProscar20,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRenflexis65,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRosuzet5,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductSingulair48,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductVtama35,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductVytorin21,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductZetia96,000,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductArcoxia59,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductAtozet85,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductBrenzys20,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductClarinex31,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductCozaar Hyzaar57,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductDiprospan35,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductDulera35,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductEmgality Ravvow54,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductFollistim AQ61,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductFosamax29,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductGanirelix Acetate Injection26,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductHadlima67,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductJada5,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductMarvelon Mercilon26,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductNasonex65,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductNexplanon Implanon NXT201,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductNuva Ring24,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOntruzant5,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Biosimilars24,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Cardiovascular28,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Non Opiod Pain Bone And Dermatology68,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Respiratory12,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Sundry Established Brands87,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Sundry Products18,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductOther Womens Health46,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductPropecia30,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductProscar26,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductRenflexis57,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductRosuzet6,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductSingulair40,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductVtama25,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductVytorin21,000,000USD0001628280-26-029532
    Q1 2026Quarterly · 2026-03-31ProductZetia87,000,000USD0001628280-26-029532
    Q4 2025Quarterly · 2025-12-31ProductArcoxia69,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductAtozet66,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductBrenzys21,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductClarinex30,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductCozaar Hyzaar53,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductDiprospan38,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductDulera35,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductEmgality Ravvow49,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductFollistim AQ57,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductFosamax36,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductGanirelix Acetate Injection25,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductHadlima68,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductJada21,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductMarvelon Mercilon24,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductNasonex64,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductNexplanon Implanon NXT210,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductNuva Ring15,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOntruzant19,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Biosimilars12,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Cardiovascular29,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Non Opiod Pain Bone And Dermatology73,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Respiratory13,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Sundry Established Brands85,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Sundry Products16,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Womens Health46,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductPropecia27,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductProscar24,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRenflexis61,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRosuzet8,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductSingulair59,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductVtama39,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductVytorin25,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductZetia90,000,000USDLegacy provider

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.